Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review

Table 1 Summary of combination treatments for hepatocellular carcinoma patients with portal vein tumor thrombosis

	Overall survival (mo)	Extent of PVTT (mo)		Ref.
		Main PVTT	Branch PVTT
BSC	2-4			Llovet et al[3], Schöniger-Hekele et al[5]
Sorafenib	6.5-8.1			Llovet et al[9], Cheng et al[11]
TACE	7-10	5.3	10	Chung et al[21], Luo et al[22]
HAIC	6.5-14			Park et al[26], Ando et al[27], Eun et al[28]
RT	9.6-10.9			Toya et al[39], Nakazawa et al[40]
TARE	6-16.9	7.7	16.9	Salem et al[47], Kulik et al[49], Sangro et al[48], Memon et al[50]
TACE plus sorafenib	11-13	3	13-15	Pan et al[58], Zhu et al[59]
Sorafenib plus RT	8.6-10.6			Chen et al[53], Chow et al[61]
TACE plus RT	10.6-12	12		Yoon et al[64], Chung et al[72], Kim et al[73]
HAIC plus RT	12.1			Fujino et al[76]

BSC: Best supportive care; TACE: Transarterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; RT: Radiation therapy; TARE: Transarterial radioembolization; PVTT: Portal vein thrombosis.